Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
| Autor: | Molly C. Hardebeck, Holly Rene Martin, Stephen R. D. Johnston, Miguel Martín, Joyce O'Shaughnessy, Masakazu Toi, Jens Huober, Matthew P. Goetz, Valerie Andre, Joohyuk Sohn |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty medicine.drug_class Population ECOG Performance Status Brief Communication Placebo Metastasis 03 medical and health sciences Breast cancer 0302 clinical medicine Internal medicine medicine Pharmacology (medical) Radiology Nuclear Medicine and imaging education Phase III trials RC254-282 education.field_of_study Aromatase inhibitor business.industry Hazard ratio Cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens Progesterone Receptor Status medicine.disease Confidence interval 030104 developmental biology 030220 oncology & carcinogenesis business |
| Zdroj: | npj Breast Cancer, Vol 7, Iss 1, Pp 1-5 (2021) NPJ Breast Cancer |
| ISSN: | 2374-4677 |
| Popis: | In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2− advanced breast cancer. We report data for clinically prognostic subgroups: liver metastases, progesterone receptor status, tumor grade, bone-only disease, ECOG performance status, and treatment-free interval (TFI) from an additional 12-month follow-up (after final progression-free survival [PFS] readout). In the intent-to-treat population, after median follow-up of approximately 39 months, the updated PFS was 28.2 versus 14.8 months (hazard ratio [HR], 0.525; 95% confidence interval, 0.415–0.665) in abemaciclib versus placebo arms, respectively. Time to chemotherapy (HR, 0.513), time to second disease progression (HR, 0.637), and duration of response (HR, 0.466) were also statistically significantly prolonged with the addition of abemaciclib to AI. Treatment benefit was observed across all subgroups, as evidenced by objective response rate change from the addition of abemaciclib to AI, with the largest effects observed in patients with liver metastases, progesterone receptor-negative tumors, high-grade tumors, or TFI |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|